What is HC Wainwright’s Estimate for Valneva Q1 Earnings?

Valneva SE (NASDAQ:VALN) – Analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Valneva in a research report issued to clients and investors on Thursday, January 23rd. HC Wainwright analyst E. White anticipates that the company will earn ($0.38) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $18.00 target price on the stock. The consensus estimate for Valneva’s current full-year earnings is $0.15 per share. HC Wainwright also issued estimates for Valneva’s Q2 2025 earnings at ($0.29) EPS, Q3 2025 earnings at ($0.31) EPS and Q4 2025 earnings at ($0.31) EPS.

Valneva Stock Up 2.4 %

Shares of NASDAQ:VALN opened at $4.74 on Friday. Valneva has a 52-week low of $3.62 and a 52-week high of $9.50. The company has a 50-day simple moving average of $4.28 and a 200 day simple moving average of $5.80. The company has a current ratio of 2.78, a quick ratio of 2.25 and a debt-to-equity ratio of 0.70.

Institutional Investors Weigh In On Valneva

A hedge fund recently raised its stake in Valneva stock. AlphaCentric Advisors LLC lifted its stake in shares of Valneva SE (NASDAQ:VALN) by 33.7% in the third quarter, according to the company in its most recent filing with the SEC. The fund owned 118,000 shares of the company’s stock after buying an additional 29,748 shares during the quarter. AlphaCentric Advisors LLC owned about 0.15% of Valneva worth $717,000 as of its most recent SEC filing. 11.39% of the stock is owned by institutional investors.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.